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Background: The Cytochrome P450 1B1 (CYP1B1) is a key P450 enzyme involved in the metabolism of exogenous
and endogenous substrates. Previous studies have reported the existence of CYP1B1 L432V missense polymorphism
in prostate, bladder and renal cancers. However, the effects of this polymorphism on the risk of these cancers
remain conflicting. Therefore, we performed a meta-analysis to assess the association between L432V polymorphism
and the susceptibility of urinary cancers.
Methods: We searched the PubMed database without limits on language for studies exploring the relationship of
CYP1B1 L432V polymorphism and urinary cancers. Article search was supplemented by screening the references of
retrieved studies manually. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated to evaluate the
strength of these associations. Simultaneously, publication bias was estimated by funnel plot and Begg’s test with
Stata 11 software.
Results: We observed a significant association between CYP1B1 L432V polymorphism and urinary cancers. The
overall OR (95% CI) of CC versus CG was 0.937 (0.881-0.996), the overall OR (95% CI) of CC versus CG + GG was
0.942 (0.890-0.997). Furthermore, we identified reduced risk for CC versus other phenotypes in both prostate and
overall urinary cancers, when studies were limited to Caucasian or Asian patients.
Conclusions: This meta-analysis suggests that the CYP1B1 L432V polymorphism is associated with urinary cancer
risk.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/3108829721231527
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Prostate cancer, urothelial carcinoma and renal cancer
are common cancer types and major cause of cancer-
related death worldwide [1,2]. Smoking, diet and envir-
onmental factors have been reported to contribute to
the carcinogenesis of these malignancies [3,4]. However,
the fact that a small fraction of people exposed to these
carcinogens eventually develop urinary cancers suggests
that individual genetic predisposition factors may con-
tribute to carcinogenesis.
Cytochrome P450 1B1 (CYP1B1) is a member of the
CYP1 gene family and one of the major enzymes involved* Correspondence: jiangweifan163@126.com
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unless otherwise stated.in the hydroxylation of estrogens, involved in the oxidative
activation and deactivation of xenobiotics [5-7]. Several
polymorphisms in the CYP1B1 gene have been reported,
including 4326C/G (L432V, rs1056836) in exon 3, which
encodes the heme-binding domain, have been associated
with enhanced catalytic activity when compared to the
wild-type allele [8-10].
Polymorphisms in XPC and MHTFR gene have been
reported to be associated with overall urinary cancer risk
[11,12], suggesting that urinary cancers share common
mechanisms in the process of DNA repair and carcinogen
metabolism. Several case–control studies were performed
to identify the association of CYP1B1 polymorphisms with
prostate, bladder and renal cancer risk. However, small
sample sizes and limited populations in study design have
often yielded inclusive results among the studies [13-29].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The flow chart of the included studies in the
meta-analysis.
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difference ethnic backgrounds and relatively small sample
sizes. To validate the potential association between the
CYP1B1 Leu432Val polymorphism and urinary cancer
risk, we conducted a meta-analysis of data reported in 17
studies including 7,944 cases and 7,389 controls.
Methods
Publication search
Medline, PubMed, Embase and Web of Science were
searched for all relevant articles with the following terms:
“Cytochrome P450 1B1” or “CYP1B1”, “polymorphism” or
“variant”, “case–control”, “risk”, “association”, “prostate
cancer”, “bladder cancer” and “renal cancer” (last search
was updated on Feb 10, 2014). References of the retrieved
articles on this topic were also manually screened for
additional relevant eligible studies.
Selection criteria
We defined inclusion criteria as follows: written in English;
case–control design; sufficient information for estimating
odds ratio (OR) and their 95% confidence interval (CI); ob-
served genotype frequencies in the controls in agreement
with Hardy-Weinberg equilibrium (HWE). Abstracts and
unpublished reports were not considered. Investigations in
subjects with family history or cancer-prone disposition
were also excluded. Meanwhile, if studies had overlapping
subjects, we selected the most recent study that included
the largest number of individuals in the publications. This
study was approved by the ethics committee of the Second
Affiliated Hospital of Nanchang University.
Data extraction
Two investigators independently extracted the following
information from each study: the first author, year of
publication, country of origin, ethnicity, source of con-
trols (population-based, hospital-based and mixed con-
trols), genotyping method, number of genotyped cases
and controls, number of genotypes for three CYP1B1
polymorphisms in cases and controls, and main findings.
Statistical methods
Hardy–Weinberg equilibrium (HWE) was evaluated for
each study, using the goodness-of-fit chi-square test.
P < 0.05 was considered representative of departure from
HWE. Crude OR with 95% CI was used to assess the
strength of association between the three CYP1B1 L432V
polymorphism and urinary cancer risk. Then, we cal-
culated the pooled ORs and 95% CIs. Heterogeneity as-
sumption was checked by the chi-square-based Q-test. A
P value greater than 0.10 for the Q-test indicates a lack of
heterogeneity among studies, so the pooled OR estimate
of the each study was calculated by the fixed-effects model
(the Mantel–Haenszel method), the random-effects model(the Der-Simonian and Laird method) was used otherwise
[30,31]. To assess the effects of individual studies on the
overall risk of cancer, sensitivity analysis was performed by
excluding each study at a time individually and recalcu-
lating the ORs and 95% CIs. We also used the inverted
funnel plot and the Egger’s test to examine the potential
influence of publication bias (linear regression analysis).
The significance of the intercept was determined by the
t-test suggested by Egger (P < 0.05 was considered repre-
sentative of statistically significant publication bias) [32].
All statistical tests were two-sided, and a P-value of < 0.05
was considered statistically significant. Statistical tests were
performed with STATA version 11.0 (Stata Corporation,




We identified a total of 71 relevant publications after ini-
tial screening. Among these, 26 publications had met the
inclusion criteria and were subjected to further examin-
ation. We excluded 4 publications because they did not
present detailed genotyping information. We also exclu-
ded 5 publications because they did not include L432V
polymorphism. Our final data consisted of 10 publications
with a total of 5949 cases and 5388 controls for prostate
cancer, 5 publications with 1658 cases and 1593 controls
for bladder cancer, 2 publications with 337 cases and 408
controls for renal cancer (Figure 1). Of these, there were
10 hospital-based studies and 7 population-based studies.
Characteristics of included studies are summarized in
Table 1.
Quantitative synthesis
Table 2 lists the main results of this meta-analysis. Over-
all, significant associations were found between CYP1B1
L432V polymorphism and urinary cancer risk when all
Table 1 Characteristics of studies included in the meta-analysis for an association between CYP1B1 L432V SNP and risk
of urinary cancer











Holt, 2013 USA Caucasian PB 1256/1235 0.41 1 blood SNPlex
Catsburg C, 2012 USA Caucasian PB 1433/760 0.47 1 blood Taqman
Beuten J, 2008 USA Caucasian PB 649/738 0.39 1 blood Taqman
Berndt, 2007 USA Mixed PB 486/611 0.47 1 blood TaqMan
Cussenot O, 2007 France Caucasian HB 1053/837 0.39 1 blood TaqMan
Sobti RC, 2006 India Asian PB 100/100 0.18 0.415 blood PCR–RFLP
Cicek MS, 2005 USA Mixed HB 439/479 0.47 1 blood PCR–RFLP
Fukatsu, 2004 Japan Asian HB 136/255 0.29 0.947 blood PCR–RFLP
Chang BL, 2003 USA Mixed HB 310/182 0.44 0.807 ND Sequencing
Tanaka Y, 2002 Japan Asian PB 117/200 0.18 0.857 ND AS-PCR
Bladder cancer
Berber U, 2013 Turkey Asian PB 114/114 0.27 0.499 tissue AS-PCR
Salinas-Sánchez AS, 2012 Spain Caucasian HB 208/208 0.39 0.875 blood Sequencing
Fontana L, 2009 France Caucasian HB 51/45 0.58 0.104 blood TaqMan
Figueroa J, 2008 Spain Caucasian HB 1084/1012 0.42 1 blood/buccal TaqMan
Hung RJ, 2004 Italy Caucasian HB 201/214 0.59 0.888 ND PCR–RFLP
Renal cancer
Salinas-Sánchez AS, 2012 Spain Caucasian HB 126/208 0.39 0.875 blood Sequencing
Sasaki M, 2005 USA Asian HB 211/200 0.18 0.857 tissue AS-PCR
Abbreviations: SNP Single nucleotide polymorphism, HB Hospital based, PB Population based, RFLP Restriction fragment length polymorphisms, AS-PCR Allele
specific PCR, ND Not described. aStatistical power to detect an OR of 1.5 (or 0.67 = 1/1.5).
Table 2 Meta-analysis of the associations between CYP1B1 L432V polymorphism and urinary cancer risk
Cancer Number of studies Cases/controls Comparison Test of association Test of heterogeneity Publication bias
OR 95% CI P Value Q P Value I2(%) P Value (Begg’s)
Prostate 10 5949/5388 CC vs GG 0.942 0.868-1.022 0.151 20.23 0.017 55.5 0.917
CC vs CG 0.947 0.881-1.018 0.137 23.13 0.006 61.1 0.212
CC vs CG + GG 0.952 0.895-1.013 0.120 20.00 0.018 55.0 0.671
C vs G 0.963 0.920-1.008 0.108 24.36 0.004 63.0 0.723
Bladder 5 1658/1593 CC vs GG 1.061 0.962-1.171 0.234 2.23 1 0.0 0.035
CC vs CG 1.000 0.926-1.079 0.991 7.20 0.126 44.4 0.317
CC vs CG + GG 1.016 0.947-1.090 0.661 6.25 0.181 36.0 0.156
C vs G 1.026 0.977-1.077 0.312 3.75 0 0.0 0.060
Renal 2 337/408 CC vs GG 0.740 0.593-0.922 0.007 0.73 0.394 0 -
CC vs CG 0.816 0.686-0.969 0.021 1.34 0.248 25.2 -
CC vs CG + GG 0.787 0.673-0.922 0.003 1.35 0.245 26.0 -
C vs G 0.818 0.729-0.917 0.001 1.82 0.178 45 -
Overall 17 7944/7389 CC vs GG 0.941 0.876-1.012 0.103 35.2 0.004 54.6 0.607
CC vs CG 0.937 0.881-0.996 0.037 37.29 0.002 57.1 0.076
CC vs CG + GG 0.942 0.890-0.997 0.038 37.97 0.002 57.9 0.199
C vs G 0.957 0.917-0.998 0.039 46.07 0 65.3 0.302
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Figure 2 Forest plot (Random effects model) describing the association of the CYP1B1 L432V polymorphism with risk of urinary
cancers. The CC phenotype was associated with a modestly decreased risk of urinary cancers (a, CC vs CG; b, CC vs CG + GG).
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OR = 0.937, 95% CI = 0.881-0.996; CC vs CG +GG:
OR = 0.942, 95% CI = 0.890-0.997; C vs G: OR = 0.957,
95% CI = 0.917-0.998) (Figure 2). In the subgroup ana-
lysis, L432V polymorphism was significantly associated
with prostate cancer or overall urinary cancer risk when
population was defined as only Caucasians or Asians
(Additional file 1: Table S1). Nevertheless, when studies
were restricted to population-based or hospital-based
studies, none of these comparisons showed significant
differences. The FPRP values for significant findings at
different prior probability levels were also calculated. For
a prior probability of 0.1, assuming that the OR for spe-
cific genotype was 0.67/1.50 (protection/risk), the FPRP
values were 0.786, 0.79 and 0.794 for an association of
overall CC vs CG, CC vs CG +GG and C vs G genotypes
with an increased lung cancer risk.
Heterogeneity and sensitivity analyses
Heterogeneities were observed among studies for the
association between the CYP1B1 L432V polymorphism
and urinary cancer risk (CC vs GG, CC vs CG, CC vs
CG +GG, C vs G for prostate cancer; C vs G for bladder
cancer; CC vs GG, CC vs CG, CC vs CG +GG, C vs G
for overall urinary cancers). Therefore, we used the
random-effects model that generated wider CIs. For the
other groups of comparisons, no heterogeneity was
found among studies and the fixed-effects model was
performed (Table 2, Additional file 1: Table S1). The
leave-one-out sensitivity analysis indicated that no single
study changed the pooled ORs qualitatively (data not
shown).
Publication bias
The shapes of the funnel plots seemed symmetrical, and
Egger’s test suggested that publication bias was only
found in the CC vs GG group of bladder cancer (Table 2,
Additional file 1: Table S1).
In this meta-analysis, we tested the association between
L432V polymorphism in the CYP1B1 gene and urinary
cancer risk by comparing the allele frequencies from 17
published studies. We observed a significant association of
L432V polymorphism with overall urinary cancer risk, as
well as in the subgroups defined as Caucasian or Asian
populations. Urinary system tumorigenesis is a complex
event, in which different carcinogenic chemicals are in-
volved. Prostate is a hormone-responsive organ in which
androgens are believed to stimulate growth and secretory
functions. Evidences have been shown that CYP1B1 pro-
tein is highly expressed in prostate cancer tissues, while
not in normal prostate tissues [33]. It has been reported
that different allelic variants of CYP1B1 have different
catalytic activities and specificities to procarcinogens,
thus partly explains molecular mechanism of CYP1B1 incarcinogenesis [34]. Except for prostate cancer, case–con-
trol studies have shown inconsistent associations between
CYP1B1 L432V polymorphism and bladder cancer and
renal cancer risk [24,28,29]. However, exact mechanisms
of how CYP1B1 polymorphism contributes to urinary can-
cer susceptibility requires further illustration.
Some limitations of this meta-analysis should be
discussed. First, the total number of included studies of
bladder cancer and renal cancer was relatively small.
Second, our results were based on unadjusted estimates,
while a more precise analysis is needed if individual data
were available, which would allow for the adjustment
by other factors such as age, smoking status, drinking
status. Finally, unpublished data may have not been
included in the current analysis, potentially causing a
bias in the results.
Conclusions
In conclusion, this meta-analysis suggests that the
CYP1B1 L432V polymorphism is associated with urinary
cancer development, especially in specified Caucasian
and Asian populations. However, studies with larger
number of samples from homogeneous urinary cancer
patients are needed. Further biological investigations
may eventually lead to better understanding of the asso-
ciation between the CYP1B1 polymorphism and urinary
cancer risk.
Additional file
Additional file 1: Table S1. Subgroup analysis of association between
CYP1B1 L432V polymorphism and urinary cancer risk.
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